Prosight Management, LP Clovis Oncology, Inc. Transaction History

Prosight Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $1.76 Million - $9.65 Million	-587,626 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $540,870 - $2.11 Million	137,626 Added 30.58%	587,626 $2.31 Million
Q2 2019 Aug 14, 2019	BUY	$12.81 - $25.67 $2.57 Million - $5.15 Million	200,611 Added 80.44%	450,000 $6.69 Million
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $3.34 Million - $5.73 Million	189,289 Added 314.96%	249,389 $6.19 Million
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $698,963 - $1.96 Million	60,100 New	60,100 $1.08 Million
Q2 2018 Aug 14, 2018	SELL	$42.06 - $62.4 $1.93 Million - $2.87 Million	-46,001 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$50.12 - $67.72 $300,770 - $406,387	6,001 Added 15.0%	46,001 $2.43 Million
Q4 2017 Feb 13, 2018	BUY	$57.69 - $84.58 $2.31 Million - $3.38 Million	40,000	40,000 $2.72 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.